Is Grace Therapeutics, Inc. (GRCE) Halal?
Shariah Screening — 5 Standards
Based on financial data from March 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 37.1% / 30% | 0.2% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 37.1% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 30.7% / 33% | 0.2% / 33% | N/A | ✓ HALAL |
| S&P | 0.0% / 33% | 37.1% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 30.7% / 33% | 0.2% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -10.2% | |
| Return on Assets (ROA) | -10.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$15M |
| Free Cash Flow | -$15M |
| Current Ratio | 15.0 |
| Total Assets | $72M |
Price & Trading
| Last Close | $4.77 |
| 50-Day MA | $3.95 |
| 200-Day MA | $3.36 |
| Avg Volume | 209K |
| Beta | 0.8 |
|
52-Week Range
$1.75
| |
About Grace Therapeutics, Inc. (GRCE)
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Grace Therapeutics, Inc. (GRCE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Grace Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Grace Therapeutics, Inc.'s debt ratio?
Grace Therapeutics, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Grace Therapeutics, Inc.'s key financial metrics?
Grace Therapeutics, Inc. has a market capitalization of $72M. Return on equity stands at -10.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.